GranisetronSerotonin 5-HT3 receptor antagonist CAS# 109889-09-0 |
- Vilazodone
Catalog No.:BCC2040
CAS No.:163521-12-8
- SB 271046 hydrochloride
Catalog No.:BCC1924
CAS No.:209481-24-3
- Adoprazine
Catalog No.:BCC1329
CAS No.:222551-17-9
- SEA0400
Catalog No.:BCC1941
CAS No.:223104-29-8
- Tianeptine
Catalog No.:BCC1999
CAS No.:66981-73-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 109889-09-0 | SDF | Download SDF |
PubChem ID | 3510 | Appearance | Powder |
Formula | C18H24N4O | M.Wt | 312.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | 25℃: DMSO | ||
Chemical Name | 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide | ||
SMILES | CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C | ||
Standard InChIKey | MFWNKCLOYSRHCJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Granisetron Dilution Calculator
Granisetron Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.2009 mL | 16.0046 mL | 32.0092 mL | 64.0184 mL | 80.023 mL |
5 mM | 0.6402 mL | 3.2009 mL | 6.4018 mL | 12.8037 mL | 16.0046 mL |
10 mM | 0.3201 mL | 1.6005 mL | 3.2009 mL | 6.4018 mL | 8.0023 mL |
50 mM | 0.064 mL | 0.3201 mL | 0.6402 mL | 1.2804 mL | 1.6005 mL |
100 mM | 0.032 mL | 0.16 mL | 0.3201 mL | 0.6402 mL | 0.8002 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: 17uM (GR reduced 5-HT-evoked contractions) [1] Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. in vitro: In rat forestomach GR reduced 5-HT-evoked contractions at IC50 17 /- 6 uM. In isolated rabbit heart, GR 0.003-0.03 nM dose-dependently reduced s-HT tachycardia; at high levels GR reduced submaximal and maximal responses to 5-HT [1]. in vivo: Leukocyte accumulation was dose-dependently inhibited by granisetron both at 6 and 72 h after induction of inflammation. Granisetron increased PGE(2) level at a lower dose (50 microg/pouch) but higher doses (100 and 200 microg/pouch) inhibited the release. At the same time, TNFalpha production was decreased by the lower dose and increased by higher doses of granisetron in a reciprocal fashion [2]. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation [3]. Clinical trial: Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects. Phase 1
- CGS 9343B
Catalog No.:BCC7303
CAS No.:109826-27-9
- Kaempferol 5,7,4'-trimethyl ether
Catalog No.:BCN6587
CAS No.:1098-92-6
- Harmalidine
Catalog No.:BCN5889
CAS No.:109794-97-0
- ASP3026
Catalog No.:BCC1372
CAS No.:1097917-15-1
- 9R-10alpha-Hydroxyepigambogic acid
Catalog No.:BCN3079
CAS No.:1097882-33-1
- Homopahutoxin
Catalog No.:BCN1812
CAS No.:109777-68-6
- 8 beta-(4-Acetoxy-5-hydroxytigloyloxy)costunolide
Catalog No.:BCN7123
CAS No.:109770-86-7
- cis-Dehydroosthol
Catalog No.:BCN4735
CAS No.:109741-40-4
- Murraol
Catalog No.:BCN5888
CAS No.:109741-38-0
- MLN 2480
Catalog No.:BCC1771
CAS No.:1096708-71-2
- SPK-601
Catalog No.:BCC1961
CAS No.:1096687-52-3
- Neocryptotanshinone
Catalog No.:BCN3158
CAS No.:109664-02-0
- Sodium prasterone sulfate
Catalog No.:BCC9149
CAS No.:1099-87-2
- Kifunensine
Catalog No.:BCC7601
CAS No.:109944-15-2
- ITD 1
Catalog No.:BCC6409
CAS No.:1099644-42-4
- Succinic acid
Catalog No.:BCN5890
CAS No.:110-15-6
- Maleic acid
Catalog No.:BCN8426
CAS No.:110-16-7
- Fumaric acid
Catalog No.:BCN5989
CAS No.:110-17-8
- Sorbic acid
Catalog No.:BCN2218
CAS No.:110-44-1
- 8-O-Ethylyunaconitine
Catalog No.:BCN6260
CAS No.:110011-77-3
- Taurohyodeoxycholic Acid Sodium Salt
Catalog No.:BCC8363
CAS No.:110026-03-4
- Tussilagonone
Catalog No.:BCC8365
CAS No.:110042-38-1
- Calpain Inhibitor I, ALLN
Catalog No.:BCC1233
CAS No.:110044-82-1
- Strophantin K (mixture)
Catalog No.:BCC8256
CAS No.:11005-63-3
Granisetron and carvedilol can protect experimental rats againstadjuvant-induced arthritis.[Pubmed:28211304]
Immunopharmacol Immunotoxicol. 2017 Apr;39(2):97-104.
CONTEXT: Rheumatoid arthritis (RA), a disabling autoimmune disorder of the joints as well as other organs, affects about 1% of population. Unfortunately, all current treatments of RA cause severe gastrointestinal, renal and other complications. OBJECTIVE: We aimed to evaluate the possible antiarthritic effects of a serotonin 5-HT3 receptor blocker, Granisetron, and a nonselective adrenergic receptor blocker, carvedilol, on complete Freund's adjuvant-induced RA in adult female albino rats. MATERIALS AND METHODS: Rats were allocated into a normal control group, an arthritis control group, two reference treatment groups receiving dexamethasone (1.5 mg/kg/day) and methotrexate (1 mg/kg/day), and two treatment groups receiving Granisetron (2.5 mg/kg/day) and carvedilol (10 mg/kg/day). Serum-specific rheumatoid, immunological, inflammatory and oxidative stress biomarkers were assessed. A confirmatory histopathological study on joints and spleens was performed. RESULTS: Granisetron administration significantly improved all the measured biomarkers, with the values of rheumatoid factor, matrix metalloproteinase-3, cartilage oligomeric matrix protein, immunoglobulin G, antinuclear antibody and myeloperoxidase being restored back to normal levels. Carvedilol administration significantly improved all biomarkers, with serum MPO value restored back to normal levels. DISCUSSION AND CONCLUSIONS: Serotonin 5-HT3 receptor blockers and adrenergic receptor blockers, represented by Granisetron and carvedilol, may represent new promising protective strategies against RA, at least owing to immune-modulator, anti-inflammatory and antioxidant potentials.
Observational Case Series Evaluation of the Granisetron Transdermal Patch System (Sancuso) for the Management of Nausea/Vomiting of Pregnancy.[Pubmed:28231602]
Am J Perinatol. 2017 Jul;34(9):851-855.
Objective The objective of this study was to observe the efficacy of antiemetic therapy (no emesis/retching episodes and no rescue medication use) when Granisetron is administered via a transdermal patch system (TDS) in women who are 6 to 14 weeks pregnant when compared with oral ondansetron by evaluating the frequency of the use of rescue medications for control of nausea/vomiting of pregnancy (NVP). Methods This was an observational case series study to observe the potential benefits of Granisetron TDS compared with oral ondansetron for management of NVP in pregnant patients during the first trimester. Dates of data collection were September 1, 2014, through December 31, 2015. There was no direct contact with patient. The oral ondansetron and Granisetron TDS patients were matched by age, 4:1. The proportion of patients who received rescue antiemetics was calculated from those patients who continued to experience NVP. Risk factors for NVP were identified and compared between groups. Descriptive statistics were used to describe study results. Results Patients were prescribed rescue antiemetics in 0/3 patients in the Granisetron TDS group compared with 2/12 patients in the oral ondansetron group. Conclusion Prospective efficacy studies on the use of Granisetron TDS for management of NVP are needed to confirm this clinical observation.
Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.[Pubmed:28061543]
Chin Clin Oncol. 2016 Dec;5(6):79.
BACKGROUND: The Granisetron transdermal delivery system (GTDS) has been demonstrated effectiveness in the control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of GTDS in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China. METHODS: A total of 313 patients were randomized into the GTDS group (one transdermal Granisetron patch, 7 days) or the oral Granisetron group (Granisetron oral 2 mg/day, >/=2 days). The primary endpoint was the percentage of patients achieving complete control (CC) from chemotherapy initiation until 24 h after final administration (PEEP). Chi-square test and Fisher's exact test were used for statistical analysis. RESULTS: Two hundred eighty-one patients were included in the per protocol analysis. During PEEP, CC was achieved by 67 (47.52%) patients in the GTDS group and 83 (59.29%) patients in the oral Granisetron group. There was no statistical significance between the groups (P=0.0559). However, the difference of the CC percentage mainly occurred on the first day of chemotherapy between the groups. The CC was 70.13% on day 1 in the GTDS group, which was significantly lower than that of 91.03% in the oral Granisetron group in the full analysis set. In the following days of chemotherapy, the CC was similar between the groups. In terms of cisplatin-contained regimen and female, there was statistical significance between the groups. Both treatments were well tolerated and safe. The most common adverse event was constipation. CONCLUSIONS: GTDS provided effective and well-tolerated control of CINV in Chinese patients, especially to non-cisplatin-contained regimen.
Simultaneous Determination of Dexamethasone, Ondansetron, Granisetron, Tropisetron, and Azasetron in Infusion Samples by HPLC with DAD Detection.[Pubmed:28168082]
J Anal Methods Chem. 2017;2017:6749087.
A simple and rapid high-performance liquid chromatography with diode array detector (HPLC-DAD) method has been developed and validated for simultaneous quantification of five antiemetic agents in infusion samples: dexamethasone, ondansetron, Granisetron, tropisetron, and azasetron. The chromatographic separation was achieved on a Phenomenex C18 column (4.6 mm x 150 mm, 5 mum) using acetonitrile-50 mM KH2PO4 buffer-triethylamine (25 : 74 : 1; v/v; pH 4.0). Flow rate was 1.0 mL/min with a column temperature of 30 degrees C. Validation of the method was made in terms of specificity, linearity, accuracy, and intra- and interday precision, as well as quantification and detection limits. The developed method can be used in the laboratory to routinely quantify dexamethasone, ondansetron, Granisetron, tropisetron, and azasetron simultaneously and to evaluate the physicochemical stability of referred drugs in mixtures for endovenous use.